VNTR News
Archived Headlines
- US IPO Week Ahead: A Huntsman spinoff, a rare bone disease biotech, and Snap's lock-up 07/28/17
- Huntsman spinoff Venator Materials sets terms for $477 million IPO 07/24/17
- US IPO Week Ahead: A real estate brokerage, a bank and a biotech 07/21/17
- US IPO Weekly Recap: 2 health care companies price, Snap breaks 07/14/17
- Huntsman spin-off Venator Materials files for a $100 million IPO 05/05/17
Renaissance Capital's 3Q17 US IPO Market Review
IPO Market Enters Fourth Quarter with the Wind at its Back The US IPO market saw 29 IPOs raise $4.1 billion in the third quarter, a drop from the prior year period. Small-cap health care companies, mostly biotechs, made up almost half of all...read more
US IPO Week Ahead: No IPOs during the final week of the August lull
There are no IPOs scheduled to price in the week ahead. While nothing is currently on the calendar, expect that to change after Labor Day, when recent filers start launching. With just five IPOs this month (six, including the one SPAC), August 2017 will be...read more
US IPO Weekly Recap: Two IPOs start off the annual August lull
Two IPOs raised a combined $574 million this past week and notched modest gains. Pigments supplier Venator Materials raised $454 million and ultra-rare bone disease biotech Clementia Pharmaceuticals raised $120 million. July 2017 was the ...read more
Venator Materials prices IPO at $20, the low end of the range
Venator Materials, a manufacturer of titanium dioxide pigments and additives spun out of Huntsman, raised $454 million by offering 22.7 million shares at $20, the low end of the range of $20 to $22. Venator Materials plans to list on the NYSE under the symbol...read more